Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetes Mellitus, Type 1 | 14 | 2025 | 819 | 1.470 |
Why?
|
Neoplasm Recurrence, Local | 18 | 2025 | 1171 | 1.270 |
Why?
|
Maximum Tolerated Dose | 17 | 2025 | 167 | 1.050 |
Why?
|
Neoplasms | 17 | 2025 | 2807 | 1.000 |
Why?
|
Central Nervous System Neoplasms | 7 | 2025 | 209 | 1.000 |
Why?
|
Child | 99 | 2025 | 24766 | 0.980 |
Why?
|
Adolescent | 79 | 2025 | 19548 | 0.900 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 1262 | 0.890 |
Why?
|
Proton Therapy | 6 | 2023 | 128 | 0.840 |
Why?
|
Child, Preschool | 64 | 2025 | 14221 | 0.820 |
Why?
|
Female | 117 | 2025 | 67333 | 0.740 |
Why?
|
Male | 110 | 2025 | 62031 | 0.740 |
Why?
|
Humans | 162 | 2025 | 126330 | 0.730 |
Why?
|
Drug Resistance, Neoplasm | 9 | 2024 | 745 | 0.610 |
Why?
|
Autism Spectrum Disorder | 6 | 2021 | 395 | 0.590 |
Why?
|
Young Adult | 36 | 2025 | 9174 | 0.580 |
Why?
|
Singing | 2 | 2016 | 6 | 0.560 |
Why?
|
Eosinophilic Esophagitis | 4 | 2021 | 77 | 0.550 |
Why?
|
Health Knowledge, Attitudes, Practice | 6 | 2021 | 858 | 0.540 |
Why?
|
Parents | 11 | 2025 | 1028 | 0.540 |
Why?
|
Pyridines | 4 | 2021 | 240 | 0.530 |
Why?
|
Brain Neoplasms | 6 | 2022 | 1324 | 0.520 |
Why?
|
Protein Kinase Inhibitors | 6 | 2021 | 558 | 0.500 |
Why?
|
Food Hypersensitivity | 4 | 2021 | 155 | 0.490 |
Why?
|
Diabetic Ketoacidosis | 4 | 2024 | 161 | 0.480 |
Why?
|
Peanut Hypersensitivity | 3 | 2022 | 78 | 0.470 |
Why?
|
Quality of Life | 10 | 2024 | 1954 | 0.460 |
Why?
|
Asthma | 4 | 2024 | 762 | 0.450 |
Why?
|
Urinary Catheterization | 2 | 2013 | 57 | 0.450 |
Why?
|
Anesthesiology | 3 | 2022 | 95 | 0.450 |
Why?
|
Infant | 34 | 2024 | 12681 | 0.440 |
Why?
|
Heart Arrest | 3 | 2024 | 359 | 0.440 |
Why?
|
Cyclopentanes | 2 | 2024 | 20 | 0.440 |
Why?
|
Cognition | 5 | 2022 | 734 | 0.440 |
Why?
|
Education, Professional | 1 | 2013 | 11 | 0.430 |
Why?
|
Liver Diseases | 3 | 2023 | 375 | 0.430 |
Why?
|
Internship and Residency | 5 | 2024 | 1189 | 0.430 |
Why?
|
Voice Disorders | 1 | 2013 | 18 | 0.430 |
Why?
|
Adult | 44 | 2025 | 29802 | 0.420 |
Why?
|
Neuroblastoma | 4 | 2023 | 530 | 0.420 |
Why?
|
Pyrazoles | 4 | 2021 | 313 | 0.410 |
Why?
|
Vocal Cords | 1 | 2013 | 66 | 0.410 |
Why?
|
Rheumatic Heart Disease | 3 | 2019 | 38 | 0.400 |
Why?
|
Arachis | 3 | 2022 | 78 | 0.390 |
Why?
|
Salvage Therapy | 3 | 2019 | 189 | 0.390 |
Why?
|
Anti-Bacterial Agents | 4 | 2019 | 2406 | 0.390 |
Why?
|
Pilot Projects | 12 | 2025 | 1413 | 0.370 |
Why?
|
Sarcoma, Ewing | 3 | 2022 | 111 | 0.370 |
Why?
|
Truth Disclosure | 3 | 2018 | 102 | 0.370 |
Why?
|
Acetylcysteine | 2 | 2023 | 72 | 0.370 |
Why?
|
Resource Allocation | 1 | 2011 | 52 | 0.370 |
Why?
|
Occupational Health | 1 | 2011 | 43 | 0.360 |
Why?
|
Hemorrhagic Disorders | 2 | 2022 | 18 | 0.360 |
Why?
|
Astronauts | 1 | 2011 | 45 | 0.360 |
Why?
|
Monte Carlo Method | 1 | 2011 | 97 | 0.360 |
Why?
|
Simulation Training | 3 | 2024 | 140 | 0.360 |
Why?
|
Health Status Indicators | 1 | 2011 | 123 | 0.360 |
Why?
|
Pyrimidines | 2 | 2024 | 389 | 0.350 |
Why?
|
von Willebrand Diseases | 2 | 2022 | 51 | 0.350 |
Why?
|
Adrenal Cortex Hormones | 3 | 2024 | 323 | 0.340 |
Why?
|
Health Behavior | 1 | 2013 | 387 | 0.340 |
Why?
|
Spinal Cord Injuries | 1 | 2013 | 303 | 0.340 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 3 | 2020 | 46 | 0.340 |
Why?
|
Retrospective Studies | 32 | 2024 | 16517 | 0.340 |
Why?
|
Menorrhagia | 2 | 2022 | 75 | 0.340 |
Why?
|
Urinary Tract Infections | 1 | 2013 | 236 | 0.330 |
Why?
|
Rhabdomyosarcoma | 2 | 2023 | 193 | 0.330 |
Why?
|
Space Flight | 1 | 2011 | 107 | 0.330 |
Why?
|
Clinical Competence | 8 | 2024 | 1008 | 0.330 |
Why?
|
Sirolimus | 2 | 2024 | 227 | 0.320 |
Why?
|
Prospective Studies | 16 | 2022 | 6175 | 0.320 |
Why?
|
Craniospinal Irradiation | 2 | 2021 | 65 | 0.320 |
Why?
|
Diabetic Retinopathy | 2 | 2021 | 156 | 0.310 |
Why?
|
Induction Chemotherapy | 2 | 2020 | 44 | 0.300 |
Why?
|
Anemia, Sickle Cell | 2 | 2024 | 333 | 0.300 |
Why?
|
Psychometrics | 3 | 2021 | 652 | 0.300 |
Why?
|
Kidney Failure, Chronic | 4 | 2018 | 890 | 0.290 |
Why?
|
Follow-Up Studies | 15 | 2024 | 5204 | 0.290 |
Why?
|
Staphylococcus aureus | 3 | 2020 | 466 | 0.280 |
Why?
|
Professional Competence | 2 | 2018 | 97 | 0.280 |
Why?
|
Allergens | 4 | 2021 | 257 | 0.280 |
Why?
|
Physician-Patient Relations | 2 | 2024 | 435 | 0.280 |
Why?
|
Hydrocortisone | 3 | 2018 | 221 | 0.280 |
Why?
|
Treatment Outcome | 21 | 2025 | 12380 | 0.280 |
Why?
|
Antineoplastic Agents, Immunological | 2 | 2020 | 121 | 0.270 |
Why?
|
Anxiety | 1 | 2013 | 949 | 0.270 |
Why?
|
Cystic Fibrosis | 2 | 2023 | 258 | 0.270 |
Why?
|
Tonsillectomy | 2 | 2021 | 101 | 0.270 |
Why?
|
Aortic Aneurysm | 3 | 2014 | 232 | 0.260 |
Why?
|
Self Report | 5 | 2022 | 513 | 0.260 |
Why?
|
Socioeconomic Factors | 6 | 2020 | 867 | 0.250 |
Why?
|
Echocardiography, Doppler, Color | 2 | 2016 | 113 | 0.250 |
Why?
|
Killer Cells, Natural | 2 | 2019 | 330 | 0.250 |
Why?
|
Vaccines | 2 | 2021 | 367 | 0.250 |
Why?
|
Glutathione Transferase | 1 | 2006 | 157 | 0.250 |
Why?
|
Health Personnel | 3 | 2024 | 513 | 0.240 |
Why?
|
Antineoplastic Agents | 3 | 2021 | 1725 | 0.240 |
Why?
|
Pain, Postoperative | 3 | 2013 | 264 | 0.240 |
Why?
|
Curriculum | 6 | 2023 | 735 | 0.240 |
Why?
|
Urea Cycle Disorders, Inborn | 2 | 2023 | 78 | 0.240 |
Why?
|
Telemedicine | 2 | 2022 | 448 | 0.240 |
Why?
|
Hydrazines | 1 | 2025 | 30 | 0.240 |
Why?
|
Drug Resistant Epilepsy | 2 | 2018 | 210 | 0.240 |
Why?
|
Immunoglobulin A | 2 | 2024 | 207 | 0.240 |
Why?
|
Vaccination | 3 | 2021 | 970 | 0.240 |
Why?
|
Time Factors | 14 | 2019 | 6334 | 0.230 |
Why?
|
Cardiopulmonary Resuscitation | 2 | 2019 | 322 | 0.230 |
Why?
|
Neoplasms, Second Primary | 1 | 2006 | 143 | 0.230 |
Why?
|
Communication | 5 | 2024 | 521 | 0.230 |
Why?
|
Biomarkers | 8 | 2024 | 3153 | 0.230 |
Why?
|
Pregnancy Complications, Infectious | 4 | 2019 | 458 | 0.230 |
Why?
|
Hospitals, Pediatric | 6 | 2019 | 771 | 0.220 |
Why?
|
Triazoles | 1 | 2025 | 140 | 0.220 |
Why?
|
Heart-Assist Devices | 3 | 2018 | 1028 | 0.220 |
Why?
|
Developmental Disabilities | 2 | 2021 | 716 | 0.220 |
Why?
|
Particulate Matter | 1 | 2024 | 71 | 0.220 |
Why?
|
Staphylococcal Infections | 3 | 2013 | 561 | 0.220 |
Why?
|
Peer Group | 1 | 2024 | 118 | 0.210 |
Why?
|
Surveys and Questionnaires | 9 | 2021 | 3716 | 0.210 |
Why?
|
Glycine | 2 | 2023 | 168 | 0.210 |
Why?
|
Blood Glucose | 4 | 2024 | 1142 | 0.210 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2023 | 794 | 0.210 |
Why?
|
Diabetes Mellitus | 2 | 2021 | 885 | 0.210 |
Why?
|
Insulin Infusion Systems | 1 | 2023 | 65 | 0.210 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2024 | 1282 | 0.210 |
Why?
|
Patient Acceptance of Health Care | 2 | 2025 | 431 | 0.210 |
Why?
|
Age Factors | 9 | 2024 | 2835 | 0.210 |
Why?
|
Glutathione | 2 | 2023 | 197 | 0.210 |
Why?
|
Phenylbutyrates | 1 | 2023 | 58 | 0.200 |
Why?
|
Middle Aged | 21 | 2024 | 27031 | 0.200 |
Why?
|
Polymorphism, Genetic | 1 | 2006 | 820 | 0.200 |
Why?
|
Blood Glucose Self-Monitoring | 1 | 2023 | 123 | 0.200 |
Why?
|
Mentors | 1 | 2024 | 153 | 0.200 |
Why?
|
Texas | 12 | 2021 | 3587 | 0.200 |
Why?
|
Craniopharyngioma | 1 | 2023 | 35 | 0.200 |
Why?
|
Patient Compliance | 3 | 2019 | 471 | 0.200 |
Why?
|
Caregivers | 3 | 2017 | 548 | 0.200 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2023 | 215 | 0.200 |
Why?
|
Self-Help Devices | 1 | 2022 | 11 | 0.200 |
Why?
|
Pneumococcal Vaccines | 1 | 2024 | 169 | 0.200 |
Why?
|
Cholecystectomy, Laparoscopic | 2 | 2013 | 44 | 0.200 |
Why?
|
Transition to Adult Care | 1 | 2024 | 118 | 0.200 |
Why?
|
Cell Phone | 1 | 2022 | 30 | 0.190 |
Why?
|
Skin Tests | 2 | 2019 | 77 | 0.190 |
Why?
|
Alagille Syndrome | 1 | 2022 | 47 | 0.190 |
Why?
|
Decision Support Techniques | 2 | 2018 | 297 | 0.190 |
Why?
|
Neutropenia | 2 | 2021 | 197 | 0.190 |
Why?
|
Pituitary Neoplasms | 1 | 2023 | 82 | 0.190 |
Why?
|
Social Determinants of Health | 1 | 2023 | 127 | 0.190 |
Why?
|
Feasibility Studies | 5 | 2025 | 771 | 0.190 |
Why?
|
Lymphoma, B-Cell | 1 | 2023 | 146 | 0.190 |
Why?
|
Autoantibodies | 3 | 2024 | 434 | 0.190 |
Why?
|
Pediatrics | 3 | 2016 | 1161 | 0.190 |
Why?
|
Postoperative Complications | 7 | 2021 | 3078 | 0.190 |
Why?
|
Head and Neck Neoplasms | 1 | 2006 | 502 | 0.180 |
Why?
|
Seizures | 2 | 2017 | 873 | 0.180 |
Why?
|
Health Literacy | 1 | 2022 | 77 | 0.180 |
Why?
|
Disabled Persons | 1 | 2022 | 92 | 0.180 |
Why?
|
Prognosis | 9 | 2024 | 4742 | 0.180 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2006 | 665 | 0.180 |
Why?
|
Educational Measurement | 3 | 2018 | 324 | 0.180 |
Why?
|
Length of Stay | 2 | 2019 | 1325 | 0.180 |
Why?
|
Sleep Apnea Syndromes | 1 | 2022 | 75 | 0.180 |
Why?
|
Pyrazines | 1 | 2021 | 73 | 0.180 |
Why?
|
HIV Infections | 3 | 2019 | 1906 | 0.170 |
Why?
|
Checklist | 2 | 2019 | 86 | 0.170 |
Why?
|
Self-Management | 2 | 2020 | 99 | 0.170 |
Why?
|
Hypoplastic Left Heart Syndrome | 2 | 2014 | 257 | 0.170 |
Why?
|
Insulin Resistance | 2 | 2023 | 645 | 0.170 |
Why?
|
Cholestasis | 1 | 2022 | 155 | 0.170 |
Why?
|
Aspartate Aminotransferases | 2 | 2023 | 85 | 0.170 |
Why?
|
Mass Screening | 2 | 2016 | 785 | 0.170 |
Why?
|
Elasticity Imaging Techniques | 1 | 2022 | 131 | 0.170 |
Why?
|
Muscle Strength | 1 | 2021 | 82 | 0.170 |
Why?
|
Hematopoietic Stem Cell Mobilization | 1 | 2020 | 26 | 0.170 |
Why?
|
Benzamides | 1 | 2021 | 114 | 0.170 |
Why?
|
Antibodies, Monoclonal, Humanized | 3 | 2024 | 515 | 0.170 |
Why?
|
Risk Factors | 13 | 2023 | 10375 | 0.170 |
Why?
|
Sleep Apnea, Obstructive | 2 | 2021 | 214 | 0.170 |
Why?
|
Protons | 2 | 2022 | 94 | 0.170 |
Why?
|
Lymphoma | 1 | 2023 | 322 | 0.170 |
Why?
|
Liver Glycogen | 1 | 2020 | 23 | 0.170 |
Why?
|
Anesthesia, Caudal | 1 | 2020 | 15 | 0.170 |
Why?
|
Photons | 2 | 2021 | 49 | 0.170 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2020 | 91 | 0.170 |
Why?
|
Severity of Illness Index | 8 | 2023 | 2933 | 0.170 |
Why?
|
Adhesins, Bacterial | 1 | 2020 | 75 | 0.170 |
Why?
|
Palliative Care | 2 | 2014 | 440 | 0.170 |
Why?
|
House Calls | 1 | 2020 | 37 | 0.160 |
Why?
|
Cross-Sectional Studies | 8 | 2024 | 3457 | 0.160 |
Why?
|
Tomography, Optical Coherence | 2 | 2021 | 528 | 0.160 |
Why?
|
Salmonella Infections | 1 | 2019 | 31 | 0.160 |
Why?
|
Hydroxyurea | 1 | 2020 | 83 | 0.160 |
Why?
|
Knowledge | 1 | 2019 | 51 | 0.160 |
Why?
|
Argininosuccinate Lyase | 1 | 2020 | 60 | 0.160 |
Why?
|
Brain Edema | 1 | 2020 | 69 | 0.160 |
Why?
|
Biofilms | 1 | 2020 | 86 | 0.160 |
Why?
|
Genes, Bacterial | 1 | 2020 | 214 | 0.160 |
Why?
|
Cell Cycle Proteins | 2 | 2023 | 654 | 0.160 |
Why?
|
Computer-Assisted Instruction | 1 | 2019 | 51 | 0.160 |
Why?
|
Prevalence | 7 | 2024 | 2484 | 0.160 |
Why?
|
Patient-Centered Care | 2 | 2020 | 225 | 0.160 |
Why?
|
Models, Educational | 1 | 2019 | 74 | 0.160 |
Why?
|
Intelligence | 2 | 2019 | 100 | 0.160 |
Why?
|
Reproducibility of Results | 7 | 2021 | 2900 | 0.160 |
Why?
|
Oxidative Stress | 2 | 2023 | 828 | 0.160 |
Why?
|
Disinfection | 2 | 2022 | 26 | 0.160 |
Why?
|
Postpartum Hemorrhage | 1 | 2020 | 98 | 0.160 |
Why?
|
Anaphylaxis | 2 | 2017 | 82 | 0.160 |
Why?
|
Cross Infection | 1 | 2022 | 316 | 0.160 |
Why?
|
Polymers | 1 | 2019 | 109 | 0.150 |
Why?
|
Webcasts as Topic | 1 | 2018 | 6 | 0.150 |
Why?
|
Glucose | 1 | 2023 | 881 | 0.150 |
Why?
|
Mobile Applications | 1 | 2020 | 93 | 0.150 |
Why?
|
Steroids | 1 | 2020 | 203 | 0.150 |
Why?
|
Videotape Recording | 1 | 2018 | 57 | 0.150 |
Why?
|
Syphilis, Congenital | 1 | 2019 | 28 | 0.150 |
Why?
|
GABA Modulators | 1 | 2018 | 11 | 0.150 |
Why?
|
Cerebellar Neoplasms | 1 | 2023 | 445 | 0.150 |
Why?
|
Schools | 2 | 2017 | 221 | 0.150 |
Why?
|
Adenoidectomy | 2 | 2021 | 77 | 0.150 |
Why?
|
Pentobarbital | 1 | 2018 | 20 | 0.150 |
Why?
|
Liver Transplantation | 2 | 2018 | 1077 | 0.150 |
Why?
|
Hyperkalemia | 1 | 2019 | 68 | 0.150 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2020 | 162 | 0.150 |
Why?
|
Blood Group Incompatibility | 1 | 2018 | 27 | 0.150 |
Why?
|
ABO Blood-Group System | 1 | 2018 | 66 | 0.150 |
Why?
|
Ultrasonography, Interventional | 1 | 2020 | 191 | 0.150 |
Why?
|
Airway Management | 1 | 2018 | 63 | 0.150 |
Why?
|
Retina | 1 | 2021 | 458 | 0.150 |
Why?
|
Bone Neoplasms | 2 | 2019 | 430 | 0.150 |
Why?
|
Single-Blind Method | 4 | 2024 | 240 | 0.150 |
Why?
|
Critical Pathways | 1 | 2019 | 79 | 0.150 |
Why?
|
Furans | 1 | 2018 | 29 | 0.150 |
Why?
|
Medulloblastoma | 1 | 2023 | 550 | 0.150 |
Why?
|
Fatigue | 2 | 2017 | 188 | 0.150 |
Why?
|
Syphilis | 1 | 2019 | 97 | 0.150 |
Why?
|
Intensive Care Units, Neonatal | 2 | 2018 | 318 | 0.150 |
Why?
|
Computer Systems | 2 | 2020 | 37 | 0.150 |
Why?
|
United States | 10 | 2022 | 10990 | 0.150 |
Why?
|
Ketones | 1 | 2018 | 27 | 0.150 |
Why?
|
Penicillins | 1 | 2019 | 154 | 0.150 |
Why?
|
Prosthesis-Related Infections | 1 | 2020 | 174 | 0.150 |
Why?
|
Memory, Short-Term | 1 | 2019 | 139 | 0.150 |
Why?
|
Self Care | 2 | 2024 | 215 | 0.150 |
Why?
|
Anilides | 1 | 2018 | 56 | 0.150 |
Why?
|
Proportional Hazards Models | 5 | 2017 | 1380 | 0.140 |
Why?
|
Cancer Survivors | 1 | 2021 | 216 | 0.140 |
Why?
|
Anemia | 1 | 2022 | 344 | 0.140 |
Why?
|
Hospitalization | 2 | 2024 | 1800 | 0.140 |
Why?
|
Patient Handoff | 1 | 2018 | 24 | 0.140 |
Why?
|
Infant, Newborn | 11 | 2019 | 8308 | 0.140 |
Why?
|
Insulin | 2 | 2022 | 1207 | 0.140 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2023 | 539 | 0.140 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2020 | 1685 | 0.140 |
Why?
|
Intraoperative Care | 1 | 2018 | 107 | 0.140 |
Why?
|
Neoplasms, Muscle Tissue | 1 | 2017 | 10 | 0.140 |
Why?
|
Bacterial Infections | 1 | 2020 | 304 | 0.140 |
Why?
|
Medical Order Entry Systems | 1 | 2019 | 101 | 0.140 |
Why?
|
Interpersonal Relations | 2 | 2017 | 224 | 0.140 |
Why?
|
Walk Test | 1 | 2017 | 25 | 0.140 |
Why?
|
Drug Administration Schedule | 4 | 2020 | 730 | 0.140 |
Why?
|
Pyrrolidinones | 1 | 2017 | 17 | 0.140 |
Why?
|
Vaccination Refusal | 1 | 2017 | 18 | 0.140 |
Why?
|
Pregnancy | 9 | 2024 | 7257 | 0.140 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2017 | 26 | 0.140 |
Why?
|
Administration, Oral | 4 | 2021 | 700 | 0.140 |
Why?
|
Civil Defense | 1 | 2017 | 8 | 0.140 |
Why?
|
School Nursing | 1 | 2017 | 8 | 0.140 |
Why?
|
Hodgkin Disease | 1 | 2020 | 292 | 0.140 |
Why?
|
Enterocolitis | 1 | 2017 | 28 | 0.140 |
Why?
|
Liver Cirrhosis | 3 | 2023 | 877 | 0.140 |
Why?
|
Renal Replacement Therapy | 1 | 2018 | 146 | 0.140 |
Why?
|
Inflammation | 2 | 2023 | 1462 | 0.140 |
Why?
|
Nurse's Role | 1 | 2017 | 39 | 0.140 |
Why?
|
Irritable Bowel Syndrome | 1 | 2020 | 205 | 0.140 |
Why?
|
Anesthetics, Intravenous | 2 | 2014 | 46 | 0.130 |
Why?
|
Simian virus 40 | 1 | 2018 | 196 | 0.130 |
Why?
|
alpha7 Nicotinic Acetylcholine Receptor | 1 | 2017 | 58 | 0.130 |
Why?
|
Autistic Disorder | 1 | 2020 | 351 | 0.130 |
Why?
|
Diet Therapy | 1 | 2017 | 43 | 0.130 |
Why?
|
Electrocorticography | 1 | 2017 | 71 | 0.130 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2017 | 131 | 0.130 |
Why?
|
Anesthetics, Inhalation | 2 | 2014 | 45 | 0.130 |
Why?
|
Fathers | 1 | 2017 | 70 | 0.130 |
Why?
|
Status Epilepticus | 1 | 2018 | 149 | 0.130 |
Why?
|
Disaster Planning | 1 | 2017 | 63 | 0.130 |
Why?
|
Cardiologists | 1 | 2016 | 20 | 0.130 |
Why?
|
Rheumatic Diseases | 1 | 2017 | 70 | 0.130 |
Why?
|
Patient Education as Topic | 1 | 2020 | 443 | 0.130 |
Why?
|
Medical Errors | 1 | 2018 | 154 | 0.130 |
Why?
|
Immunophenotyping | 1 | 2017 | 327 | 0.130 |
Why?
|
Hematologic Diseases | 1 | 2017 | 79 | 0.130 |
Why?
|
Phonation | 1 | 2016 | 6 | 0.130 |
Why?
|
Guideline Adherence | 2 | 2018 | 379 | 0.130 |
Why?
|
Neurosurgical Procedures | 1 | 2019 | 303 | 0.130 |
Why?
|
Voice Training | 1 | 2016 | 5 | 0.130 |
Why?
|
Rituximab | 1 | 2017 | 157 | 0.130 |
Why?
|
Quinolines | 1 | 2017 | 106 | 0.130 |
Why?
|
Glioma | 1 | 2021 | 515 | 0.130 |
Why?
|
Cardiopulmonary Bypass | 1 | 2018 | 355 | 0.130 |
Why?
|
Sodium Potassium Chloride Symporter Inhibitors | 1 | 2016 | 32 | 0.130 |
Why?
|
Voice Quality | 1 | 2016 | 19 | 0.130 |
Why?
|
Learning | 1 | 2019 | 364 | 0.130 |
Why?
|
Lymphocytes | 1 | 2018 | 409 | 0.130 |
Why?
|
Gastrointestinal Diseases | 1 | 2020 | 343 | 0.130 |
Why?
|
Pneumonia, Pneumocystis | 1 | 2016 | 39 | 0.130 |
Why?
|
Air Ambulances | 1 | 2016 | 24 | 0.130 |
Why?
|
Decision Making | 2 | 2018 | 671 | 0.130 |
Why?
|
Patient Readmission | 2 | 2019 | 393 | 0.130 |
Why?
|
Malawi | 4 | 2019 | 399 | 0.130 |
Why?
|
Intelligence Tests | 1 | 2016 | 59 | 0.130 |
Why?
|
Device Removal | 2 | 2017 | 217 | 0.120 |
Why?
|
Chronic Disease | 4 | 2023 | 1204 | 0.120 |
Why?
|
Dietary Proteins | 1 | 2017 | 253 | 0.120 |
Why?
|
Attitude to Health | 1 | 2017 | 256 | 0.120 |
Why?
|
Cardiotonic Agents | 1 | 2017 | 140 | 0.120 |
Why?
|
Myocardial Contraction | 1 | 2017 | 265 | 0.120 |
Why?
|
Emergency Medical Technicians | 1 | 2016 | 40 | 0.120 |
Why?
|
Informed Consent | 1 | 2018 | 336 | 0.120 |
Why?
|
Bacteremia | 1 | 2019 | 401 | 0.120 |
Why?
|
Registries | 6 | 2019 | 1454 | 0.120 |
Why?
|
RNA, Viral | 1 | 2018 | 538 | 0.120 |
Why?
|
Vasodilator Agents | 1 | 2017 | 203 | 0.120 |
Why?
|
Shellfish Hypersensitivity | 1 | 2015 | 5 | 0.120 |
Why?
|
Fentanyl | 2 | 2013 | 47 | 0.120 |
Why?
|
Heart Defects, Congenital | 3 | 2018 | 1838 | 0.120 |
Why?
|
Morphine | 2 | 2013 | 83 | 0.120 |
Why?
|
School Health Services | 1 | 2016 | 99 | 0.120 |
Why?
|
Cardiac Catheterization | 1 | 2019 | 635 | 0.120 |
Why?
|
Self-Injurious Behavior | 1 | 2016 | 64 | 0.120 |
Why?
|
Shellfish | 1 | 2015 | 31 | 0.120 |
Why?
|
Immunosuppressive Agents | 2 | 2018 | 653 | 0.120 |
Why?
|
Multivariate Analysis | 5 | 2017 | 1436 | 0.120 |
Why?
|
Community Health Services | 1 | 2016 | 90 | 0.120 |
Why?
|
Pneumonia, Bacterial | 1 | 2016 | 78 | 0.120 |
Why?
|
Basement Membrane | 1 | 2015 | 48 | 0.120 |
Why?
|
Larynx | 1 | 2016 | 72 | 0.120 |
Why?
|
Hypoglycemic Agents | 1 | 2019 | 448 | 0.120 |
Why?
|
Drug Utilization | 1 | 2016 | 162 | 0.120 |
Why?
|
Physicians | 2 | 2018 | 603 | 0.120 |
Why?
|
Cognition Disorders | 1 | 2019 | 550 | 0.120 |
Why?
|
Education, Medical, Graduate | 2 | 2024 | 525 | 0.120 |
Why?
|
Immunologic Deficiency Syndromes | 1 | 2017 | 207 | 0.120 |
Why?
|
Lupus Nephritis | 1 | 2015 | 42 | 0.120 |
Why?
|
Waiting Lists | 1 | 2016 | 239 | 0.120 |
Why?
|
Education, Medical, Continuing | 1 | 2016 | 143 | 0.110 |
Why?
|
Respiration Disorders | 1 | 2014 | 32 | 0.110 |
Why?
|
Hemorrhagic Fever, Ebola | 1 | 2015 | 58 | 0.110 |
Why?
|
Anti-Inflammatory Agents | 1 | 2017 | 296 | 0.110 |
Why?
|
Social Support | 1 | 2017 | 350 | 0.110 |
Why?
|
Ulna | 1 | 2014 | 6 | 0.110 |
Why?
|
Hypoxia-Ischemia, Brain | 1 | 2015 | 81 | 0.110 |
Why?
|
Phenotype | 3 | 2022 | 4323 | 0.110 |
Why?
|
Tracheostomy | 1 | 2017 | 198 | 0.110 |
Why?
|
Longitudinal Studies | 4 | 2020 | 1341 | 0.110 |
Why?
|
Mothers | 1 | 2017 | 357 | 0.110 |
Why?
|
Recombinant Fusion Proteins | 1 | 2017 | 771 | 0.110 |
Why?
|
Radius | 1 | 2014 | 26 | 0.110 |
Why?
|
Wrist Joint | 1 | 2014 | 25 | 0.110 |
Why?
|
Tissue Inhibitor of Metalloproteinases | 1 | 2014 | 22 | 0.110 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2017 | 226 | 0.110 |
Why?
|
End Stage Liver Disease | 1 | 2016 | 194 | 0.110 |
Why?
|
Pollen | 1 | 2014 | 46 | 0.110 |
Why?
|
Renal Dialysis | 3 | 2016 | 862 | 0.110 |
Why?
|
Tissue Distribution | 3 | 2019 | 393 | 0.110 |
Why?
|
Logistic Models | 5 | 2017 | 1812 | 0.110 |
Why?
|
Lost to Follow-Up | 1 | 2014 | 33 | 0.110 |
Why?
|
Community-Acquired Infections | 1 | 2016 | 240 | 0.110 |
Why?
|
Aged | 10 | 2023 | 19962 | 0.110 |
Why?
|
Foreign Bodies | 1 | 2015 | 106 | 0.110 |
Why?
|
Sodium Hypochlorite | 1 | 2013 | 7 | 0.110 |
Why?
|
Hypothermia, Induced | 1 | 2015 | 169 | 0.110 |
Why?
|
Postnatal Care | 1 | 2014 | 51 | 0.110 |
Why?
|
Baths | 1 | 2013 | 16 | 0.110 |
Why?
|
Fungi | 1 | 2014 | 70 | 0.110 |
Why?
|
Reinforcement Schedule | 1 | 2013 | 4 | 0.110 |
Why?
|
Matrix Metalloproteinases | 1 | 2014 | 67 | 0.110 |
Why?
|
Speech-Language Pathology | 1 | 2013 | 13 | 0.110 |
Why?
|
Hypoglycemia | 1 | 2015 | 193 | 0.110 |
Why?
|
Chromosome Disorders | 1 | 2016 | 310 | 0.110 |
Why?
|
Hygiene | 1 | 2013 | 27 | 0.110 |
Why?
|
Disinfectants | 1 | 2013 | 25 | 0.110 |
Why?
|
Biliary Atresia | 1 | 2016 | 191 | 0.110 |
Why?
|
Esophagus | 1 | 2015 | 223 | 0.110 |
Why?
|
Airway Extubation | 1 | 2014 | 68 | 0.110 |
Why?
|
Hyperglycemia | 1 | 2015 | 228 | 0.110 |
Why?
|
Intraoperative Complications | 1 | 2014 | 171 | 0.100 |
Why?
|
Ventricular Function, Left | 1 | 2017 | 520 | 0.100 |
Why?
|
HIV Seronegativity | 1 | 2013 | 28 | 0.100 |
Why?
|
Office Visits | 1 | 2013 | 77 | 0.100 |
Why?
|
Renal Insufficiency | 1 | 2015 | 242 | 0.100 |
Why?
|
Bacteriuria | 1 | 2013 | 47 | 0.100 |
Why?
|
Quality Improvement | 1 | 2019 | 653 | 0.100 |
Why?
|
Reward | 1 | 2013 | 111 | 0.100 |
Why?
|
Terminal Care | 1 | 2014 | 114 | 0.100 |
Why?
|
Pre-Eclampsia | 1 | 2015 | 223 | 0.100 |
Why?
|
Molecular Imaging | 1 | 2013 | 63 | 0.100 |
Why?
|
Intensive Care Units, Pediatric | 4 | 2018 | 479 | 0.100 |
Why?
|
NADPH Oxidases | 1 | 2013 | 112 | 0.100 |
Why?
|
Incidence | 5 | 2019 | 3170 | 0.100 |
Why?
|
Sexual Partners | 1 | 2013 | 87 | 0.100 |
Why?
|
Body Composition | 1 | 2015 | 532 | 0.100 |
Why?
|
Head | 1 | 2013 | 104 | 0.100 |
Why?
|
Continuity of Patient Care | 1 | 2014 | 150 | 0.100 |
Why?
|
Infant Mortality | 1 | 2013 | 176 | 0.100 |
Why?
|
Tympanic Membrane | 1 | 2012 | 19 | 0.100 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2015 | 194 | 0.100 |
Why?
|
Perioperative Care | 1 | 2014 | 198 | 0.100 |
Why?
|
Cognitive Dysfunction | 1 | 2016 | 242 | 0.100 |
Why?
|
Disease Management | 1 | 2016 | 529 | 0.100 |
Why?
|
Otologic Surgical Procedures | 1 | 2012 | 23 | 0.100 |
Why?
|
HIV Seropositivity | 1 | 2013 | 124 | 0.100 |
Why?
|
Abdominal Muscles | 1 | 2012 | 27 | 0.100 |
Why?
|
Genes, Reporter | 1 | 2013 | 382 | 0.100 |
Why?
|
Glomerular Filtration Rate | 1 | 2015 | 513 | 0.100 |
Why?
|
Marfan Syndrome | 1 | 2014 | 142 | 0.100 |
Why?
|
HIV | 1 | 2013 | 182 | 0.090 |
Why?
|
Green Fluorescent Proteins | 1 | 2013 | 389 | 0.090 |
Why?
|
Otolaryngology | 1 | 2013 | 108 | 0.090 |
Why?
|
Anesthesia, Local | 1 | 2012 | 44 | 0.090 |
Why?
|
Practice Patterns, Physicians' | 1 | 2018 | 740 | 0.090 |
Why?
|
Thoracic Surgery | 1 | 2013 | 160 | 0.090 |
Why?
|
Diagnostic Errors | 1 | 2015 | 331 | 0.090 |
Why?
|
DNA Copy Number Variations | 1 | 2017 | 975 | 0.090 |
Why?
|
Nerve Fibers | 2 | 2021 | 75 | 0.090 |
Why?
|
Analgesics, Opioid | 2 | 2013 | 417 | 0.090 |
Why?
|
Cocaine-Related Disorders | 1 | 2013 | 201 | 0.090 |
Why?
|
Acute Kidney Injury | 1 | 2018 | 649 | 0.090 |
Why?
|
Extracorporeal Membrane Oxygenation | 1 | 2018 | 618 | 0.090 |
Why?
|
Medication Adherence | 1 | 2015 | 401 | 0.090 |
Why?
|
Magnetic Resonance Imaging | 3 | 2017 | 3622 | 0.090 |
Why?
|
Anesthetics, Local | 1 | 2012 | 85 | 0.090 |
Why?
|
MicroRNAs | 1 | 2018 | 868 | 0.090 |
Why?
|
Fellowships and Scholarships | 1 | 2014 | 286 | 0.090 |
Why?
|
Membrane Glycoproteins | 1 | 2013 | 414 | 0.090 |
Why?
|
Premature Birth | 1 | 2015 | 391 | 0.090 |
Why?
|
Lung Neoplasms | 1 | 2021 | 1668 | 0.090 |
Why?
|
Poverty | 1 | 2014 | 423 | 0.090 |
Why?
|
Desensitization, Immunologic | 2 | 2022 | 106 | 0.090 |
Why?
|
Biopsy | 3 | 2023 | 1257 | 0.090 |
Why?
|
Diabetes Complications | 1 | 2012 | 203 | 0.090 |
Why?
|
Pneumonia, Viral | 1 | 2016 | 381 | 0.090 |
Why?
|
Heart Failure | 3 | 2018 | 2309 | 0.080 |
Why?
|
Child Behavior | 1 | 2012 | 230 | 0.080 |
Why?
|
Survival Rate | 3 | 2020 | 2070 | 0.080 |
Why?
|
Neurodevelopmental Disorders | 1 | 2015 | 502 | 0.080 |
Why?
|
Aorta | 1 | 2013 | 548 | 0.080 |
Why?
|
Kidney Transplantation | 1 | 2015 | 658 | 0.080 |
Why?
|
Attitude of Health Personnel | 1 | 2015 | 678 | 0.080 |
Why?
|
Cohort Studies | 4 | 2023 | 4874 | 0.080 |
Why?
|
Tertiary Care Centers | 3 | 2017 | 245 | 0.080 |
Why?
|
Immunoglobulin M | 2 | 2024 | 216 | 0.080 |
Why?
|
von Willebrand Factor | 2 | 2022 | 198 | 0.080 |
Why?
|
Aorta, Thoracic | 1 | 2014 | 527 | 0.080 |
Why?
|
Linear Models | 3 | 2017 | 694 | 0.080 |
Why?
|
Prenatal Diagnosis | 1 | 2013 | 607 | 0.080 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2014 | 442 | 0.080 |
Why?
|
Intubation, Intratracheal | 1 | 2012 | 287 | 0.080 |
Why?
|
Sleep | 2 | 2022 | 352 | 0.080 |
Why?
|
Intellectual Disability | 1 | 2016 | 1057 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 3 | 2017 | 1073 | 0.070 |
Why?
|
United Kingdom | 2 | 2021 | 202 | 0.070 |
Why?
|
Odds Ratio | 2 | 2015 | 1266 | 0.070 |
Why?
|
Recurrence | 3 | 2017 | 1400 | 0.070 |
Why?
|
Dietary Supplements | 2 | 2023 | 474 | 0.070 |
Why?
|
Cardiac Surgical Procedures | 1 | 2017 | 1130 | 0.070 |
Why?
|
Kidney | 1 | 2015 | 1361 | 0.070 |
Why?
|
Administration, Intravenous | 2 | 2019 | 145 | 0.070 |
Why?
|
Adrenergic beta-Agonists | 2 | 2019 | 94 | 0.070 |
Why?
|
Sex Factors | 2 | 2024 | 1293 | 0.070 |
Why?
|
Brain Injuries | 1 | 2013 | 706 | 0.070 |
Why?
|
Asymptomatic Diseases | 2 | 2019 | 84 | 0.070 |
Why?
|
Risk Assessment | 4 | 2017 | 3461 | 0.070 |
Why?
|
Predictive Value of Tests | 3 | 2017 | 2194 | 0.070 |
Why?
|
Immunoglobulin E | 2 | 2019 | 165 | 0.070 |
Why?
|
Mitochondria | 2 | 2023 | 696 | 0.070 |
Why?
|
Pain Measurement | 3 | 2013 | 345 | 0.070 |
Why?
|
Potassium | 2 | 2019 | 282 | 0.070 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2015 | 741 | 0.070 |
Why?
|
Aged, 80 and over | 4 | 2021 | 6645 | 0.060 |
Why?
|
Isotretinoin | 1 | 2006 | 23 | 0.060 |
Why?
|
Mutagens | 1 | 2006 | 83 | 0.060 |
Why?
|
Canada | 2 | 2017 | 291 | 0.060 |
Why?
|
Chemoprevention | 1 | 2006 | 56 | 0.060 |
Why?
|
Chromosome Breakage | 1 | 2006 | 167 | 0.060 |
Why?
|
Bleomycin | 1 | 2006 | 153 | 0.060 |
Why?
|
Disease Progression | 3 | 2019 | 2103 | 0.060 |
Why?
|
Atherosclerosis | 1 | 2013 | 917 | 0.060 |
Why?
|
Brain | 1 | 2017 | 3034 | 0.060 |
Why?
|
Time-to-Treatment | 2 | 2020 | 190 | 0.060 |
Why?
|
Observer Variation | 2 | 2017 | 299 | 0.060 |
Why?
|
Nuclear Family | 1 | 2005 | 50 | 0.060 |
Why?
|
Aging | 2 | 2023 | 1208 | 0.060 |
Why?
|
NEDD8 Protein | 1 | 2024 | 11 | 0.060 |
Why?
|
Penetrance | 1 | 2005 | 104 | 0.060 |
Why?
|
Algorithms | 1 | 2011 | 1647 | 0.060 |
Why?
|
Anti-Retroviral Agents | 2 | 2017 | 142 | 0.060 |
Why?
|
Life Support Care | 1 | 2024 | 48 | 0.060 |
Why?
|
Methyl Ethers | 2 | 2014 | 23 | 0.060 |
Why?
|
C-Peptide | 1 | 2024 | 113 | 0.060 |
Why?
|
B-Lymphocyte Subsets | 1 | 2024 | 22 | 0.060 |
Why?
|
Propofol | 2 | 2014 | 45 | 0.050 |
Why?
|
Disease-Free Survival | 1 | 2006 | 891 | 0.050 |
Why?
|
Administration, Inhalation | 1 | 2024 | 181 | 0.050 |
Why?
|
Survival Analysis | 2 | 2018 | 1517 | 0.050 |
Why?
|
Antigens, CD | 2 | 2018 | 431 | 0.050 |
Why?
|
Pregnancy Complications, Cardiovascular | 1 | 2024 | 105 | 0.050 |
Why?
|
Alcohol Drinking | 1 | 2006 | 347 | 0.050 |
Why?
|
Vidarabine | 1 | 2023 | 77 | 0.050 |
Why?
|
Azacitidine | 1 | 2023 | 54 | 0.050 |
Why?
|
Drug Therapy, Combination | 2 | 2018 | 1168 | 0.050 |
Why?
|
Cytarabine | 1 | 2023 | 97 | 0.050 |
Why?
|
Comorbidity | 2 | 2020 | 1542 | 0.050 |
Why?
|
Genetic Linkage | 1 | 2005 | 457 | 0.050 |
Why?
|
Cell Survival | 2 | 2018 | 835 | 0.050 |
Why?
|
Spleen | 1 | 2024 | 281 | 0.050 |
Why?
|
Reoperation | 2 | 2018 | 835 | 0.050 |
Why?
|
Case-Control Studies | 3 | 2015 | 3341 | 0.050 |
Why?
|
Endoglin | 1 | 2022 | 21 | 0.050 |
Why?
|
Matrix Metalloproteinase 7 | 1 | 2022 | 21 | 0.050 |
Why?
|
Pedigree | 2 | 2017 | 1615 | 0.050 |
Why?
|
Transcription Factor 7-Like 2 Protein | 1 | 2022 | 24 | 0.050 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2023 | 145 | 0.050 |
Why?
|
Information Seeking Behavior | 1 | 2022 | 15 | 0.050 |
Why?
|
Ipilimumab | 1 | 2022 | 64 | 0.050 |
Why?
|
Echocardiography | 2 | 2019 | 1075 | 0.050 |
Why?
|
Insulin-Secreting Cells | 1 | 2024 | 148 | 0.050 |
Why?
|
Myelodysplastic Syndromes | 1 | 2023 | 127 | 0.050 |
Why?
|
Liver | 2 | 2022 | 1758 | 0.050 |
Why?
|
Immunoglobulin G | 2 | 2015 | 782 | 0.050 |
Why?
|
Emergencies | 1 | 2023 | 173 | 0.050 |
Why?
|
Emergency Service, Hospital | 2 | 2020 | 1080 | 0.050 |
Why?
|
Snoring | 1 | 2021 | 18 | 0.050 |
Why?
|
Blindness | 1 | 2022 | 75 | 0.050 |
Why?
|
Obstetrics | 1 | 2024 | 238 | 0.050 |
Why?
|
Social Adjustment | 1 | 2022 | 80 | 0.050 |
Why?
|
Pneumococcal Infections | 1 | 2024 | 275 | 0.050 |
Why?
|
Interleukin-8 | 1 | 2022 | 211 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 2 | 2017 | 3203 | 0.050 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2024 | 413 | 0.050 |
Why?
|
Acute Disease | 1 | 2024 | 1103 | 0.050 |
Why?
|
Checkpoint Kinase 2 | 1 | 2021 | 36 | 0.050 |
Why?
|
Mice | 4 | 2023 | 17881 | 0.050 |
Why?
|
Glycine Agents | 1 | 2021 | 10 | 0.050 |
Why?
|
Biological Specimen Banks | 1 | 2021 | 51 | 0.050 |
Why?
|
Checkpoint Kinase 1 | 1 | 2021 | 25 | 0.050 |
Why?
|
Osteosarcoma | 1 | 2024 | 255 | 0.040 |
Why?
|
Fibrosis | 1 | 2023 | 447 | 0.040 |
Why?
|
Free Radical Scavengers | 1 | 2021 | 50 | 0.040 |
Why?
|
Resuscitation | 1 | 2023 | 253 | 0.040 |
Why?
|
Leukopenia | 1 | 2021 | 47 | 0.040 |
Why?
|
Polysomnography | 1 | 2022 | 145 | 0.040 |
Why?
|
Body Weight | 2 | 2015 | 1004 | 0.040 |
Why?
|
Triglycerides | 1 | 2023 | 577 | 0.040 |
Why?
|
Endothelium | 1 | 2021 | 67 | 0.040 |
Why?
|
Topotecan | 1 | 2020 | 48 | 0.040 |
Why?
|
Prenatal Care | 2 | 2014 | 349 | 0.040 |
Why?
|
Smoking | 1 | 2006 | 1050 | 0.040 |
Why?
|
Retinal Ganglion Cells | 1 | 2021 | 101 | 0.040 |
Why?
|
Animals | 5 | 2023 | 34533 | 0.040 |
Why?
|
Biological Availability | 1 | 2020 | 147 | 0.040 |
Why?
|
Point-of-Care Systems | 1 | 2022 | 178 | 0.040 |
Why?
|
Palpation | 1 | 2020 | 18 | 0.040 |
Why?
|
Response Evaluation Criteria in Solid Tumors | 1 | 2020 | 8 | 0.040 |
Why?
|
Genotype | 1 | 2006 | 2594 | 0.040 |
Why?
|
Pragmatic Clinical Trials as Topic | 1 | 2020 | 24 | 0.040 |
Why?
|
Monosaccharides | 1 | 2020 | 23 | 0.040 |
Why?
|
Needles | 1 | 2020 | 52 | 0.040 |
Why?
|
Phthalazines | 1 | 2019 | 15 | 0.040 |
Why?
|
Geriatric Assessment | 1 | 2021 | 176 | 0.040 |
Why?
|
Triticum | 1 | 2019 | 36 | 0.040 |
Why?
|
Vincristine | 1 | 2020 | 193 | 0.040 |
Why?
|
Fermentation | 1 | 2020 | 70 | 0.040 |
Why?
|
Eggs | 1 | 2019 | 24 | 0.040 |
Why?
|
Internet | 1 | 2022 | 378 | 0.040 |
Why?
|
Pyrimidinones | 1 | 2019 | 51 | 0.040 |
Why?
|
Alanine Transaminase | 1 | 2020 | 158 | 0.040 |
Why?
|
Oligosaccharides | 1 | 2020 | 75 | 0.040 |
Why?
|
Survivors | 1 | 2022 | 341 | 0.040 |
Why?
|
Factor Analysis, Statistical | 1 | 2020 | 218 | 0.040 |
Why?
|
Health Promotion | 1 | 2023 | 391 | 0.040 |
Why?
|
Dendritic Cells | 1 | 2022 | 417 | 0.040 |
Why?
|
Respiratory Function Tests | 1 | 2020 | 202 | 0.040 |
Why?
|
Soft Tissue Infections | 1 | 2020 | 86 | 0.040 |
Why?
|
Doxorubicin | 1 | 2020 | 290 | 0.040 |
Why?
|
New Orleans | 1 | 2019 | 13 | 0.040 |
Why?
|
CD4-CD8 Ratio | 1 | 2019 | 12 | 0.040 |
Why?
|
Thrombocytopenia | 1 | 2021 | 225 | 0.040 |
Why?
|
Treatment Failure | 1 | 2020 | 337 | 0.040 |
Why?
|
Milk | 1 | 2019 | 119 | 0.040 |
Why?
|
Self-Assessment | 1 | 2018 | 65 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2006 | 1987 | 0.040 |
Why?
|
Achievement | 1 | 2018 | 31 | 0.040 |
Why?
|
Sarcoma | 1 | 2021 | 187 | 0.040 |
Why?
|
Cyclophosphamide | 1 | 2020 | 414 | 0.040 |
Why?
|
Hemorrhage | 1 | 2022 | 473 | 0.040 |
Why?
|
Intensive Care Units | 1 | 2022 | 501 | 0.040 |
Why?
|
Dexamethasone | 1 | 2020 | 276 | 0.040 |
Why?
|
Patient Simulation | 1 | 2018 | 39 | 0.040 |
Why?
|
Regulatory Sequences, Ribonucleic Acid | 1 | 2018 | 16 | 0.040 |
Why?
|
Goals | 1 | 2019 | 128 | 0.040 |
Why?
|
Antibodies, Monoclonal | 1 | 2024 | 1026 | 0.040 |
Why?
|
Efficiency, Organizational | 1 | 2018 | 55 | 0.040 |
Why?
|
Antigens, Polyomavirus Transforming | 1 | 2018 | 88 | 0.040 |
Why?
|
Orthopedics | 1 | 2018 | 67 | 0.040 |
Why?
|
Specialization | 1 | 2018 | 77 | 0.040 |
Why?
|
Cell Transformation, Viral | 1 | 2018 | 99 | 0.040 |
Why?
|
Receptors, Natural Killer Cell | 1 | 2017 | 6 | 0.040 |
Why?
|
Manikins | 1 | 2018 | 136 | 0.040 |
Why?
|
CD56 Antigen | 1 | 2017 | 26 | 0.040 |
Why?
|
DNA Damage | 1 | 2021 | 517 | 0.040 |
Why?
|
Microtubules | 1 | 2018 | 126 | 0.030 |
Why?
|
Pregnancy, High-Risk | 1 | 2017 | 43 | 0.030 |
Why?
|
Myeloid Cells | 1 | 2018 | 104 | 0.030 |
Why?
|
Retreatment | 1 | 2017 | 91 | 0.030 |
Why?
|
Hydrocephalus | 1 | 2020 | 244 | 0.030 |
Why?
|
Heart Rate | 1 | 2020 | 583 | 0.030 |
Why?
|
Skin | 1 | 2020 | 527 | 0.030 |
Why?
|
Phosphatidylinositol 3-Kinase | 1 | 2017 | 25 | 0.030 |
Why?
|
Clinical Protocols | 1 | 2018 | 240 | 0.030 |
Why?
|
Genome, Viral | 1 | 2018 | 167 | 0.030 |
Why?
|
Social Workers | 1 | 2017 | 6 | 0.030 |
Why?
|
Administration, Topical | 1 | 2017 | 139 | 0.030 |
Why?
|
Disease Models, Animal | 2 | 2020 | 4467 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2022 | 1129 | 0.030 |
Why?
|
Adolescent Behavior | 1 | 2019 | 170 | 0.030 |
Why?
|
Comparative Effectiveness Research | 1 | 2017 | 69 | 0.030 |
Why?
|
Standard of Care | 1 | 2018 | 130 | 0.030 |
Why?
|
Lymphocyte Subsets | 1 | 2017 | 38 | 0.030 |
Why?
|
Exome | 1 | 2022 | 1039 | 0.030 |
Why?
|
Vomiting | 1 | 2017 | 103 | 0.030 |
Why?
|
Epinephrine | 1 | 2018 | 178 | 0.030 |
Why?
|
Epilepsies, Partial | 1 | 2017 | 92 | 0.030 |
Why?
|
Family | 1 | 2020 | 566 | 0.030 |
Why?
|
Lymphocyte Count | 1 | 2017 | 119 | 0.030 |
Why?
|
Emergency Medicine | 1 | 2018 | 153 | 0.030 |
Why?
|
Pandemics | 1 | 2024 | 1129 | 0.030 |
Why?
|
Respiratory Tract Diseases | 1 | 2017 | 77 | 0.030 |
Why?
|
Neurology | 1 | 2018 | 108 | 0.030 |
Why?
|
Sound Spectrography | 1 | 2016 | 7 | 0.030 |
Why?
|
Stroboscopy | 1 | 2016 | 4 | 0.030 |
Why?
|
Remission Induction | 1 | 2017 | 297 | 0.030 |
Why?
|
Critical Care | 1 | 2022 | 661 | 0.030 |
Why?
|
Stress, Physiological | 1 | 2018 | 262 | 0.030 |
Why?
|
Legionella | 1 | 2016 | 9 | 0.030 |
Why?
|
Acoustics | 1 | 2016 | 21 | 0.030 |
Why?
|
Pneumocystis carinii | 1 | 2016 | 9 | 0.030 |
Why?
|
Comprehension | 1 | 2017 | 78 | 0.030 |
Why?
|
Medicaid | 1 | 2019 | 243 | 0.030 |
Why?
|
Pregnant Women | 1 | 2017 | 143 | 0.030 |
Why?
|
Microarray Analysis | 1 | 2017 | 235 | 0.030 |
Why?
|
Cluster Analysis | 1 | 2017 | 409 | 0.030 |
Why?
|
Chickenpox Vaccine | 1 | 2016 | 13 | 0.030 |
Why?
|
Poliovirus Vaccines | 1 | 2016 | 14 | 0.030 |
Why?
|
Haemophilus Vaccines | 1 | 2016 | 30 | 0.030 |
Why?
|
General Surgery | 1 | 2018 | 206 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 1 | 2017 | 328 | 0.030 |
Why?
|
Measles-Mumps-Rubella Vaccine | 1 | 2016 | 14 | 0.030 |
Why?
|
Potassium Radioisotopes | 1 | 2015 | 7 | 0.030 |
Why?
|
Hepatitis B Vaccines | 1 | 2016 | 42 | 0.030 |
Why?
|
Sample Size | 1 | 2016 | 88 | 0.030 |
Why?
|
Lymphadenitis | 1 | 2015 | 26 | 0.030 |
Why?
|
Research Design | 1 | 2020 | 709 | 0.030 |
Why?
|
Host-Pathogen Interactions | 1 | 2018 | 255 | 0.030 |
Why?
|
New Zealand | 1 | 2015 | 52 | 0.030 |
Why?
|
Wasting Syndrome | 1 | 2015 | 25 | 0.030 |
Why?
|
Diarrhea | 1 | 2017 | 316 | 0.030 |
Why?
|
Mycophenolic Acid | 1 | 2015 | 49 | 0.030 |
Why?
|
Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2016 | 35 | 0.030 |
Why?
|
Apgar Score | 1 | 2015 | 49 | 0.030 |
Why?
|
Mice, Inbred MRL lpr | 1 | 2015 | 16 | 0.030 |
Why?
|
Platelet Count | 1 | 2015 | 137 | 0.030 |
Why?
|
Biomechanical Phenomena | 1 | 2016 | 244 | 0.030 |
Why?
|
Antibodies, Antinuclear | 1 | 2015 | 28 | 0.030 |
Why?
|
Risk | 1 | 2017 | 769 | 0.030 |
Why?
|
Respiratory Syncytial Viruses | 1 | 2016 | 148 | 0.030 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 2015 | 43 | 0.030 |
Why?
|
Failure to Thrive | 1 | 2015 | 90 | 0.030 |
Why?
|
Tacrolimus | 1 | 2015 | 99 | 0.030 |
Why?
|
Sex Distribution | 1 | 2016 | 309 | 0.030 |
Why?
|
Chromosomes, Human, Pair 15 | 1 | 2016 | 160 | 0.030 |
Why?
|
Patient Safety | 1 | 2019 | 400 | 0.030 |
Why?
|
Respiratory Distress Syndrome, Newborn | 1 | 2016 | 81 | 0.030 |
Why?
|
Cyclosporine | 1 | 2015 | 145 | 0.030 |
Why?
|
Age Distribution | 1 | 2016 | 422 | 0.030 |
Why?
|
Flow Cytometry | 1 | 2017 | 803 | 0.030 |
Why?
|
Health Surveys | 1 | 2016 | 247 | 0.030 |
Why?
|
Prednisone | 1 | 2015 | 282 | 0.030 |
Why?
|
Perinatal Death | 1 | 2015 | 26 | 0.030 |
Why?
|
Infant, Small for Gestational Age | 1 | 2015 | 57 | 0.030 |
Why?
|
ROC Curve | 1 | 2016 | 577 | 0.030 |
Why?
|
B-Lymphocytes | 1 | 2018 | 532 | 0.030 |
Why?
|
Stroke Volume | 1 | 2017 | 501 | 0.030 |
Why?
|
Operating Rooms | 1 | 2015 | 68 | 0.030 |
Why?
|
Education, Medical | 1 | 2018 | 290 | 0.030 |
Why?
|
Oligohydramnios | 1 | 2015 | 46 | 0.030 |
Why?
|
Creatinine | 1 | 2016 | 395 | 0.030 |
Why?
|
Molecular Targeted Therapy | 1 | 2017 | 379 | 0.030 |
Why?
|
Cross Reactions | 1 | 2015 | 191 | 0.030 |
Why?
|
Patient Discharge | 1 | 2019 | 497 | 0.030 |
Why?
|
Graft Rejection | 1 | 2018 | 596 | 0.030 |
Why?
|
Positive-Pressure Respiration | 1 | 2014 | 84 | 0.030 |
Why?
|
Aftercare | 1 | 2015 | 150 | 0.030 |
Why?
|
Surgeons | 1 | 2018 | 258 | 0.030 |
Why?
|
Elastic Tissue | 1 | 2013 | 19 | 0.030 |
Why?
|
Glycosaminoglycans | 1 | 2013 | 33 | 0.030 |
Why?
|
Recovery of Function | 1 | 2016 | 438 | 0.030 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 1 | 2013 | 37 | 0.030 |
Why?
|
Elastin | 1 | 2013 | 31 | 0.030 |
Why?
|
Prosthesis Design | 1 | 2017 | 673 | 0.030 |
Why?
|
Patient Care Team | 1 | 2018 | 550 | 0.030 |
Why?
|
Activities of Daily Living | 1 | 2016 | 401 | 0.030 |
Why?
|
Streptococcus pneumoniae | 1 | 2016 | 376 | 0.030 |
Why?
|
Birth Weight | 1 | 2015 | 346 | 0.030 |
Why?
|
Isoflurane | 1 | 2013 | 41 | 0.030 |
Why?
|
Substance Abuse Detection | 1 | 2013 | 40 | 0.030 |
Why?
|
CD3 Complex | 1 | 2013 | 91 | 0.030 |
Why?
|
Combined Modality Therapy | 1 | 2017 | 1251 | 0.030 |
Why?
|
Asymptomatic Infections | 1 | 2013 | 25 | 0.030 |
Why?
|
Hospital Mortality | 1 | 2018 | 1034 | 0.030 |
Why?
|
NADPH Oxidase 2 | 1 | 2013 | 40 | 0.030 |
Why?
|
Echoencephalography | 1 | 2013 | 25 | 0.030 |
Why?
|
Graft Survival | 1 | 2015 | 540 | 0.030 |
Why?
|
Extracellular Space | 1 | 2013 | 88 | 0.030 |
Why?
|
Southwestern United States | 1 | 2013 | 43 | 0.030 |
Why?
|
Hospitals, County | 1 | 2013 | 23 | 0.030 |
Why?
|
Fluorescence | 1 | 2013 | 96 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 829 | 0.030 |
Why?
|
Macrophage Activation | 1 | 2013 | 67 | 0.030 |
Why?
|
Neoplasm Staging | 1 | 2017 | 1291 | 0.030 |
Why?
|
Fetal Growth Retardation | 1 | 2015 | 238 | 0.030 |
Why?
|
Heart Diseases | 1 | 2018 | 503 | 0.030 |
Why?
|
Nervous System Diseases | 1 | 2017 | 375 | 0.030 |
Why?
|
Postoperative Period | 1 | 2014 | 338 | 0.030 |
Why?
|
Biosensing Techniques | 1 | 2013 | 55 | 0.030 |
Why?
|
Social Participation | 1 | 2012 | 11 | 0.030 |
Why?
|
Diet | 1 | 2020 | 1150 | 0.030 |
Why?
|
Chromosome Deletion | 1 | 2016 | 656 | 0.030 |
Why?
|
Cell Line | 1 | 2018 | 2734 | 0.030 |
Why?
|
Muscle Fibers, Skeletal | 1 | 2013 | 99 | 0.020 |
Why?
|
Myocytes, Smooth Muscle | 1 | 2013 | 161 | 0.020 |
Why?
|
Infant Behavior | 1 | 2012 | 14 | 0.020 |
Why?
|
Social Stigma | 1 | 2013 | 76 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2014 | 588 | 0.020 |
Why?
|
Postpartum Period | 1 | 2014 | 216 | 0.020 |
Why?
|
Anesthesia Recovery Period | 1 | 2012 | 24 | 0.020 |
Why?
|
Body Image | 1 | 2012 | 40 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2016 | 1597 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2017 | 2068 | 0.020 |
Why?
|
Chest Tubes | 1 | 2012 | 36 | 0.020 |
Why?
|
Glycemic Index | 1 | 2012 | 19 | 0.020 |
Why?
|
Influenza Vaccines | 1 | 2017 | 481 | 0.020 |
Why?
|
Genetic Association Studies | 1 | 2016 | 788 | 0.020 |
Why?
|
Regression Analysis | 1 | 2014 | 784 | 0.020 |
Why?
|
Electric Stimulation | 1 | 2013 | 328 | 0.020 |
Why?
|
Oxidation-Reduction | 1 | 2013 | 447 | 0.020 |
Why?
|
Administration, Intranasal | 1 | 2012 | 133 | 0.020 |
Why?
|
Injections, Intravenous | 1 | 2012 | 248 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2018 | 3040 | 0.020 |
Why?
|
Surgical Instruments | 1 | 2012 | 56 | 0.020 |
Why?
|
Injections, Intramuscular | 1 | 2012 | 194 | 0.020 |
Why?
|
Radiography | 1 | 2014 | 805 | 0.020 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2014 | 243 | 0.020 |
Why?
|
Cesarean Section | 1 | 2015 | 393 | 0.020 |
Why?
|
In Vitro Techniques | 1 | 2013 | 973 | 0.020 |
Why?
|
Delirium | 1 | 2012 | 56 | 0.020 |
Why?
|
Self Concept | 1 | 2012 | 153 | 0.020 |
Why?
|
Lipopolysaccharides | 1 | 2013 | 303 | 0.020 |
Why?
|
Viral Load | 1 | 2013 | 393 | 0.020 |
Why?
|
Influenza, Human | 1 | 2017 | 666 | 0.020 |
Why?
|
Gestational Age | 1 | 2015 | 1174 | 0.020 |
Why?
|
Nerve Block | 1 | 2012 | 66 | 0.020 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2013 | 221 | 0.020 |
Why?
|
Preoperative Care | 1 | 2013 | 358 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2018 | 2394 | 0.020 |
Why?
|
Health Status | 1 | 2012 | 385 | 0.020 |
Why?
|
Reactive Oxygen Species | 1 | 2013 | 499 | 0.020 |
Why?
|
Emotions | 1 | 2012 | 349 | 0.020 |
Why?
|
DNA | 1 | 2015 | 1621 | 0.020 |
Why?
|
Body Mass Index | 1 | 2015 | 1582 | 0.020 |
Why?
|
Motor Activity | 1 | 2012 | 527 | 0.020 |
Why?
|
Muscle, Skeletal | 1 | 2015 | 980 | 0.020 |
Why?
|
Health Services Accessibility | 1 | 2014 | 611 | 0.020 |
Why?
|
Practice Guidelines as Topic | 1 | 2015 | 1274 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2012 | 1611 | 0.020 |
Why?
|
Primary Health Care | 1 | 2014 | 772 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2015 | 4466 | 0.020 |
Why?
|
Blood Vessel Prosthesis Implantation | 1 | 2014 | 768 | 0.020 |
Why?
|
Lod Score | 1 | 2005 | 120 | 0.010 |
Why?
|
Chromosome Segregation | 1 | 2005 | 61 | 0.010 |
Why?
|
Mutation | 1 | 2018 | 5965 | 0.010 |
Why?
|
Models, Genetic | 1 | 2005 | 764 | 0.010 |
Why?
|
Computational Biology | 1 | 2005 | 838 | 0.010 |
Why?
|